DNA crosslinking in cancer cells

DNA crosslinking in cancer cells refers to the process by which certain chemotherapeutic agents—most notably bifunctional alkylating agents—form covalent bonds between the two strands of cellular DNA. This prevents proper separation and replication during cell division. The resulting damage activates cellular stress responses such as p53-mediated pathways; if the damage cannot be repaired, these pathways trigger programmed cell death (apoptosis)[2]. Drugs like treosulfan and its active form DEB are used clinically for their ability to induce such lesions selectively in rapidly dividing cancer cells[1]. However, this is not a single molecular target but rather a chemical effect on nucleic acids; thus \"DNA crosslinking\" is best described as a mechanism or process rather than a discrete protein or receptor. While effective against tumors, this approach can also harm normal proliferative tissues due to its lack of specificity[1].\n\nThe entry \"Cancer cell DNA crosslinking causing apoptosis\" does not refer to an individual molecule or receptor but describes a **mechanism** by which certain drugs exert cytotoxic effects on tumor cells. It should not be considered a canonical therapeutic target like an enzyme or receptor; instead it represents an outcome induced by several classes of chemotherapeutics through direct chemical modification of cellular macromolecules[1][2].

Other names

DNA interstrand crosslinkingDNA cross-link formationbifunctional alkylating agent-induced DNA damage

Formation of covalent bonds between two strands of DNA (\"crosslinks\"), preventing separation and replication.\nActivation of p53 pathway leading to cell cycle arrest or apoptosis when repair is not possible[2].